Product Description: Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.
Applications: Cancer-Kinase/protease
Formula: C24H24FN7O
References: [1]Lanier M, et al. Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure. ACS Med Chem Lett. 2017 Feb 8;8(3):316-320./[2]Lin JH, et al. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33./[3]Loomba R, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2trial. Hepatology. 2018 Feb;67(2):549-559.
CAS Number: 1448428-04-3
Molecular Weight: 445.49
Compound Purity: 99.05
Research Area: Cancer
Solubility: DMSO : ≥ 31 mg/mL
Target: Apoptosis;MAP3K
Deutsch
English
